Biogen Inc

23 oct. 2026, 23:31 UTC

Biogen Inc shares are trading higher in after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

22 oct. 2026, 22:31 UTC

Biogen Inc shares are modestly lower in after-market trading, having retraced from earlier gains, with a cumulative return dipping to nearly 0.6%.

21 oct. 2026, 23:46 UTC

Biogen Inc is advancing in after-market trading, reaching a high near the upper end of its one-month range, maintaining a solid position above its 20-day moving average.

20 oct. 2026, 23:06 UTC

RBC Capital identifies Biogen as a top pick, maintaining an Outperform rating with a price target of $256 amid a catalyst-rich period.

19 oct. 2026, 20:13 UTC

Biogen Inc shares advanced in after-market trading, maintaining a cumulative return since Monday's close and remaining above its 20-day moving average.

16 oct. 2026, 23:16 UTC

Biogen Inc's shares are modestly higher in after-market trading, remaining above their 20-day moving average and near the upper end of their one-month range.

15 oct. 2026, 23:16 UTC

Biogen Inc shares advanced modestly in after-market trading, remaining above its 20-day moving average and near the upper end of its one-month range.

14 oct. 2026, 19:26 UTC

Shares of Biogen Inc are advancing, influenced by recent U.S. inflation reports, and remain above their 20-day moving average during Wednesday's session.

13 oct. 2026, 20:08 UTC

Biogen Inc shares are declining, following a slight drop from Monday's close.

12 oct. 2026, 22:21 UTC

Biogen Inc shares advanced during after-market hours on Monday, continuing a trend of higher movement since the prior close.

9 oct. 2026, 20:07 UTC

UBS reaffirms Buy rating on Biogen Inc and raises price target to $270 from $240, while CCB International initiates coverage with an Outperform rating.

8 oct. 2026, 20:07 UTC

RBC Capital lowers Biogen price target to $256 from $260 while maintaining an Outperform rating, reflecting ongoing evaluations of the company's performance and market conditions.

7 oct. 2026, 23:45 UTC

Biogen Inc. is seeing a modest decline in after-market trading, stabilizing at a level nearly half a percent below Wednesday's close.

6 oct. 2026, 20:06 UTC

Biogen Inc's shares fell, reflecting a slight decline from Monday's close, despite peaking in the morning and remaining near the upper end of their one-month range.

5 oct. 2026, 23:25 UTC

Biogen Inc is trading modestly lower in after-market hours, reflecting a decline since Monday's close and stabilizing within its one-month trading range.

2 oct. 2026, 23:15 UTC

Biogen Inc. has declined during after-market hours, marking its sixth consecutive session of lower closes and reaching a cumulative return low.

1 oct. 2026, 23:55 UTC

Biogen Inc is trading modestly higher in after-market hours, maintaining a position above its 20-day moving average and near its one-month range.

28 sept. 2026, 19:15 UTC

Biogen Inc is seeing a modest gain, retracing above its 20-day moving average and near the upper end of its one-month range.

25 sept. 2026, 19:26 UTC

Biogen Inc is trading slightly higher, remaining above its 20-day moving average and near the upper end of its one-month range.

24 sept. 2026, 23:05 UTC

Biogen Inc is trading modestly higher in after-market hours, reflecting solid performance above its 20-day moving average and near the upper end of its one-month range.

23 sept. 2026, 19:36 UTC

Biogen Inc is seeing modest gains as it releases adolescent subgroup data from its Phase 3 VALIANT trial of EMPAVELI, targeting rare kidney diseases.

22 sept. 2026, 23:50 UTC

Biogen Inc is trading lower in after-market hours, experiencing fluctuations despite remaining above its 20-day moving average and near the upper end of its one-month range.

21 sept. 2026, 23:05 UTC

Biogen Inc. is trading slightly higher in after-market hours following approvals for at-home LEQEMBI in Japan and China and new Phase 3 data for EMPAVELI.

18 sept. 2026, 20:02 UTC

Biogen Inc shares fell sharply, reversing a trend of higher daily closes observed in recent sessions and breaking from upward momentum since Thursday's close.

17 sept. 2026, 20:07 UTC

Biogen Inc. shares advanced after Japan approved its subcutaneous formulation of LEQEMBI®, enhancing its Alzheimer's treatment portfolio in today's trading.

16 sept. 2026, 20:21 UTC

Biogen Inc's LEQEMBI® receives approval in Japan for a new administration route, while the stock is modestly lower in after-market trading.

15 sept. 2026, 20:07 UTC

Biogen Inc shares are lower today, influenced by a drop in the NY Empire State Manufacturing Index and rising oil prices amid broader market weakness.

14 sept. 2026, 20:08 UTC

Biogen Inc. shares are advancing, supported by strong performances from key holdings in the health care sector. The broader market reflects modest gains.

11 sept. 2026, 20:08 UTC

Biogen Inc is rising after Needham named it a top biotechnology pick, maintaining a Buy rating amid expectations for future growth and clinical developments.

10 sept. 2026, 20:07 UTC

Stifel reiterated a Buy rating on Biogen and raised its price target to $242, while HSBC maintained a Reduce rating with a target increase to $175.